Literature DB >> 4360856

On the mechanism of lithium-induced diabetes insipidus in man and the rat.

J N Forrest, A D Cohen, J Torretti, J M Himmelhoch, F H Epstein.   

Abstract

The mechanism of lithium-induced diabetes insipidus was investigated in 96 patients and in a rat model. Polydipsia was reported by 40% and polyuria (more than 3 liter/day) by 12% of patients receiving lithium. Maximum concentrating ability after dehydration and vasopressin was markedly impaired in 10 polyuric patients and was reduced in 7 of 10 nonpolyuric patients studied before and during lithium therapy. Severe polyuria (more than 6 liter/day) was unresponsive to trials of vasopressin and chlorpropamide, but improved on chlorothiazide. Rats receiving lithium (3-4 meq/kg/day) developed massive polyuria that was resistant to vasopressin, in comparison to rats with comparable polyuria induced by drinking glucose. Analysis of renal tissue in rats with lithium polyuria showed progressive increase in the concentration of lithium from cortex to papilla with a 2.9-fold corticopapillary gradient for lithium. The normal corticopapillary gradient for sodium was not reduced by lithium treatment. The polyuria was not interrupted by brief intravenous doses of vasopressin (5-10 mU/kg) or dibutyryl cyclic AMP (10-15 mg/kg) capable of reversing water diuresis in normal and hypothalamic diabetes insipidus rats (Brattleboro strain). The present studies suggest that nephrogenic diabetes insipidus is a common finding after lithium treatment and results in part from interference with the mediation of vasopressin at a step distal to the formation of 3',5' cyclic AMP.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4360856      PMCID: PMC333097          DOI: 10.1172/JCI107649

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  37 in total

1.  The toxic effects, excretion and distribution of lithium chloride.

Authors:  J L RADOMSKI; H N FUYAT; A A NELSON; P K SMITH
Journal:  J Pharmacol Exp Ther       Date:  1950-12       Impact factor: 4.030

2.  Lithium-induced ADH resistance in toad urinary bladders.

Authors:  I Singer; E A Franko
Journal:  Kidney Int       Date:  1973-03       Impact factor: 10.612

3.  Thyroid secretion in vitro: inhibition of TSH and dibutyryl cyclic-AMP stimulated 131-I release by Li+1.

Authors:  J A Williams; S C Berens; J Wolff
Journal:  Endocrinology       Date:  1971-06       Impact factor: 4.736

Review 4.  Cyclic adenosine monophosphate as a mediator of hormone action.

Authors:  G W Liddle; J G Hardman
Journal:  N Engl J Med       Date:  1971-09-02       Impact factor: 91.245

5.  Effect of chlorpropamide on the permeability of the urinary bladder of the toad and the response to vasopressin, adenosine-3',5'-monophosphate and theophylline.

Authors:  S A Mendoza
Journal:  Endocrinology       Date:  1969-02       Impact factor: 4.736

6.  Antidiuresis in diabetes insipidus.

Authors:  T Morgan; H E De Wardener
Journal:  Lancet       Date:  1969-03-08       Impact factor: 79.321

7.  A behavioral-biochemical study of lithium treatment.

Authors:  W E Bunney; F K Goodwin; J M Davis; J A Fawcett
Journal:  Am J Psychiatry       Date:  1968-10       Impact factor: 18.112

8.  Chlorpropamide treatment in diabetes insipidus.

Authors:  I Froyshov; H N Haugen
Journal:  Acta Med Scand       Date:  1968-04

9.  Potentiation of the antidiuretic effect of vasopressin by chlorpropamide.

Authors:  W O Berndt; M Miller; W M Kettyle; H Valtin
Journal:  Endocrinology       Date:  1970-05       Impact factor: 4.736

10.  Effects of adenosine 3',5'-monophosphate on renal function in the rabbit.

Authors:  M A Barraclough; N F Jones
Journal:  Br J Pharmacol       Date:  1970-10       Impact factor: 8.739

View more
  38 in total

1.  Static fusimotor component of the pinna reflex.

Authors:  B L Andrew; G C Leslie; N J Part
Journal:  J Physiol       Date:  1975-02       Impact factor: 5.182

2.  The renal pathology in a case of lithium-induced diabetes insipidus.

Authors:  G B Lindop; P L Padfield
Journal:  J Clin Pathol       Date:  1975-06       Impact factor: 3.411

Review 3.  Molecular mechanisms in lithium-associated renal disease: a systematic review.

Authors:  Soham Rej; Shamira Pira; Victoria Marshe; André Do; Dominique Elie; Karl J Looper; Nathan Herrmann; Daniel J Müller
Journal:  Int Urol Nephrol       Date:  2016-06-29       Impact factor: 2.370

4.  Idiopathic oedema and prolactin.

Authors:  D C Evered; D F Horrobin; P A Vice; E N Cole; B A Nassar
Journal:  Proc R Soc Med       Date:  1976-06

5.  Structural and functional response of the isolated toad skin to mucosal lithium.

Authors:  S M Sanioto; A Sesso
Journal:  Pflugers Arch       Date:  1987-06       Impact factor: 3.657

Review 6.  Neuroendocrine markers of CNS drug effects.

Authors:  E C Johnstone; I N Ferrier
Journal:  Br J Clin Pharmacol       Date:  1980-07       Impact factor: 4.335

Review 7.  Thirty years of clinical experience with carbamazepine in the treatment of bipolar illness: principles and practice.

Authors:  Robert M Post; Terence A Ketter; Thomas Uhde; James C Ballenger
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

8.  Hydrochlorothiazide ameliorates polyuria caused by tolvaptan treatment of polycystic kidney disease in PCK rats.

Authors:  Anyi Wang; Takuo Hirose; Yusuke Ohsaki; Chika Takahashi; Emiko Sato; Ikuko Oba-Yabana; Satoshi Kinugasa; Yoshikazu Muroya; Sadayoshi Ito; Takefumi Mori
Journal:  Clin Exp Nephrol       Date:  2018-11-13       Impact factor: 2.801

Review 9.  Review of clinically important drug interactions with lithium.

Authors:  N S Harvey; S Merriman
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

10.  Lithium and the antidiuretic hormone.

Authors:  S MacNeil; G Jennings; P R Eastwood; C Paschalis; F A Jenner
Journal:  Br J Clin Pharmacol       Date:  1976-04       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.